Table 2 Corticosteroid dose and tapering scheme
From: Treatment approaches for idiopathic retroperitoneal fibrosis: a systematic review with meta-analysis
Study | n | Drug | Dose (per day) | Tapering scheme (per day) |
|---|---|---|---|---|
Van der Bilt 2016 [12] | 50 | PDN or PDNolon | 60 mg* | 60 mg for median duration of 14 months, detailed tapering scheme not described |
Labidi 2015 [78] | 30 | CST | 0.98 mg/kgBW** | At 52.3 months follow-up mean dose 9.5 mg, detailed tapering scheme not described |
Brandt 2015 [74] | 46 | PDNolon | 1 mg/kgBW (one alternate days) | 1 mg/kgBW/2d for 10 weeks 40 mg for two weeks 20 mg for two weeks 10 mg for two weeks 5 mg for one year |
Fry 2008 [75] | 24 | PDNolon | 30 mg** | Reduced during 1–2 months to 10 mg, then gradual reduction to 5 mg (for 2–3 years) |
Van Bommel 2007 [14] | 24 | PDN | 60 mg | 60 mg for six weeks reduction within 2–3 months to 10 mg 10 mg for one year |
Morin 2019 [79] | 23 | PDN | 1 mg/kgBW | 1 mg/kgBW for 4 weeks Tapered by 10 mg every 4 weeks until 20 mg Tapered by 5 mg every 4 weeks until 10 mg Tapered by 1 mg every 4 week until 7 mg 7 mg for 12–36 months |
Vaglio 2011 [54] | 18 | PDN | 1 mg/kgBW | 1 mg/kgBW for one month (max 80 mg) 0.5 mg/kgBW for one month 0.25 mg/kgBW for two months 0.2 mg/kgBW for one month 0.15 mg/kgBW for one month 7.5 mg/d for one month 5 mg/d for half a month 2.5 mg/d for half a month 2.mg/d on alternating days for half a month |
Ilie 2006 [105] | 16 | PDNolon | 40 mg | 40 mg for mean four weeks (range 1–8 weeks) Reduction 5 mg per week to 1–5 mg |
Kardar 2002 [55] | 12 | PDNolon | 60 mg (on alternate days) | 60 mg/2d for two months 40 mg for 2 weeks, 20 mg for 2 weeks, 10 mg for 2 weeks, 5 mg maintenance dose (for total two years) |
Azizi 2020 [80] | 12 | CST | 0.5–1 mg/kgBW | Tapering scheme and drug duration not mentioned |